PubMed Health⌕ Search

Biomedical subjects

F A Fitzpatrick

Publications and source records attributed to F A Fitzpatrick.

At least 37 records · Page 2Linked to original sources
PubMed1990

Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils.

Aggregation of human platelets induced by a variety of agonists was inhibited by 1-[6-[[17 beta-3-methoxyestra-1,3,5(10)-trien-17-yl] amino]hexyl]-1H-pyrrole-2,5-dionel (U-73122) (IC50 values 1-5 microM), but not by the close analog 1-[6-[[17 beta-3-methoxyestra- 1,3,5(10)-trien-17-yl]amino]hexyl]-2,5-pyrrolidine-dione (U-73343) in which pyrrolidinedione was substituted for pyrroledione. Inhibition by U-73122 was not mediated by an increase in intracellular cyclic AMP. In contrast, the production of inositol 1,4,5-trisphosphate (IP3) and the subsequent rapid increase in cytosolic Ca++ induced by either thrombin or the thromboxane-mimetic, (5Z,9 alpha, 11 alpha, 13E, 15S) 15-hydroxy-11,9-(epoxymethano)prosta- 5,13,-dien-1-oic acid (U-46619), was inhibited by U-73122 but not by U-73343. Reduction of IP3 levels appeared to reflect an inhibition of IP3 production because the hydrolysis of phosphatidyl[3H]inositol and phosphatidyl[3H]inositol 4,5-bisphosphate catalyzed by a soluble fraction from platelets was inhibited by U-73122 (Ki = 9 and 40 microM, respectively). In addition, U-73122 inhibited thromboxane B2 production induced by collagen but not that supported by exogenously added arachidonic acid, suggesting that U-73122 also inhibited receptor-coupled mobilization of arachidonic acid. After preincubation of platelets with [3H]arachidonic acid, the loss of [3H]phosphatidylinositol and accumulation of [3H]phosphatidic acid induced by thrombin was attenuated by U-73122. U-73122 did not inhibit the activities of phospholipases A2 purified either from porcine pancreas or from the venoms of Crotalus adamanteus and Naja naja. Although U-73122 inhibited neither the conversion of exogenous arachidonic acid to thromboxane B2 nor the binding of the thromboxane receptor antagonist [1S-[1 alpha, 2 beta (5Z), 3 beta, 4 alpha]]-7-[3-[[2- [2-[(phenylamino)-carbonyl]- hydrazino]methyl]-7-oxabicyclo [2.2.1]-hept-2-yl-5-heptenoic acid to platelet membranes, it was an effective inhibitor of arachidonic acid-induced aggregation of platelets. These data are consistent with the observed inhibition by U-73122 of platelet activation by the thromboxane receptor agonist, U-46619, via a mechanism that involves inhibition of a phospholipase C-dependent component(s) of signal transduction. U-73122, but not U-73343, inhibited also N-formyl-methionyl-leucyl-phenylalanine-induced aggregation of human polymorphonuclear neutrophils (PMN) and the associated production of IP3 and diacyglycerol. Diradylglycerol produced in PMN stimulated with N-formyl- methionyl-leucyl-phenylalanine was 74 +/- 7% saponifiable and inhibited by U-73122 (Ki = 2 microM).(ABSTRACT TRUNCATED AT 400 WORDS)

Arachidonic Acid↗
PubMed1979

Glass capillary gas chromatography with electron-capture detection. Separation of prostaglandins.

Glass capillary gas chromatography of the prostaglandins was performed on a system including an all-glass, solventless injector; thermostable methylphenyl-polysiloxane glass capillary columns; and a conventional electron-capture detector fitted with a make-up gas tee. The principal stable metabolites of prostaglandin endoperoxide were separated as perfluorinated derivatives in 35 min. Detection limits equal or exceed those obtained for packed column separations and electron capture detection. Prostaglandin endoperoxide metabolic profiles from mammalian cell cultures were obtained using this system. These profiling studies are not possible with other chromatographic methods because of inferior resolution and sensitivity.

Animals↗
PubMed1979

Regulatory role of cyclic adenosine 3',5'-monophosphate on the platelet cyclooxygenase and platelet function.

Thromboxane A2 plays an important role in arachidonic acid- and prostaglandin H2-induced platelet aggregation. Agents that stimulate platelet adenylate cyclase (prostaglandin I2, prostaglandin I1 and prostaglandin E1) and dibutyryl cyclic AMP inhibit both thromboxane A2 formation and arachidonate-induced aggregation in platelet-rich plasma. Despite complete suppression of aggregation with agents that elevate cyclic AMP, considerable thromboxane A2 is still formed. Prostaglandin H2-induced aggregations which bypass the cyclooxygenase regulatory step are also inhibited by agents that elevate cyclic AMP without any measurable effect on thromboxane A2 production. These data demonstrate that cyclic AMP can inhibit platelet aggregation by a mechanism independent of its ability to suppress the cyclooxygenase enzyme. Parallel experiments with washed platelet preparations suggest that they may be an inadequate model for studying the relationship between the platelet cyclooxygenase and platelet function.

Arachidonic Acids↗
PubMed1979

Prostaglandin D2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential.

B16 malignant melanoma cell lines transform arachidonic acid and its transient metabolite, prostaglandin endoperoxide H2, into prostaglandin D2. The highly metastatic line, B16 F10, forms less prostaglandin D2 compared to the moderately metastatic parent line, B16 F1. Since platelet aggregation may be one factor involved in B16 metastasis and since prostaglandin D2 inhibits platelet aggregation, this prostaglandin could affect the outcome of platelet-tumour interactions, which may contribute ultimately to metastasis. Arachidonic acid metabolism may be another one of the intrinsic biochemical properties of tumor cells that affects their metastasis. Our results suggest that quantitative release of unusual prostaglandins must be considered in this context.

Arachidonic Acids↗
PubMed1978

A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.

Two selective thromboxane A2 synthetase inhibitors, imidazole and 9,11-azoprosta-5,13-dienoic acid (azo analog I) were compared to determine their effects on the quantitative formation of thromboxane B2 and prostaglandin E2 accompanying human platelet aggregation. Azo analog I was at least 200 times more potent, on a molar basis, than imidazole in suppressing thromboxane B2 formation in either platelet-rich plasma or washed platelet suspensions aggregated with arachidonic acid or prostaglandin H2. The inhibitors differed in their effect on the aggregation response itself. Azo analog I selectively suppressed thromboxane A2 formation with an accompanying, parallel, suppression of the platelet aggregation. Imidazole selectively suppressed thromboxane A2 formation, but only suppressed the accompanying aggregation in platelet rich plasma, and not washed platelet suspensions. The results indicate that azo analog I functions by competitive inhibition of prostaglandin H2 on the thromboxane synthetase, and that imidazole, while it suppresses thromboxane A2 formation, may have an associated agonist activity that enhances platelet aggregation. The data presented support this hypothesis, and they emphasize the importance of thromboxane A2 in arachidonate mediated platelet aggregation.

Arachidonic Acids↗
PubMed1978

An antiserum against 9-deoxy-6,9-epoxy-PGF1alpha recognizes and binds PGI2 (prostacyclin).

Antibodies were prepared against 9-deoxy-6,9-epoxy-PGF1alpha, the 5,6-dihydro analog of prostacyclin (PGI2). By using as the hapten, this structurally similar, stable analog, an antibody population was developed which recognized PGI2 and reversed its influence on platelet aggregation. The antibodies also opposed the normal effect of PGI2 on the cAMP and thromboxane B2 levels during aggregation. By anticipating the cross reaction between the analog and PGI2 and by considering it beneficial, the problem of raising antibodies against an unstable compound has been circumvented.

Animals↗
PubMed1978

Prostacyclin biosynthesis in activated, stimulated and normal mouse peritoneal cell populations.

Nonspecific resistance to infectious and neoplastic disease can be enhanced by administration of "immunomodulators". The levels of enhancement can be monitored by following in vitro function of cells of the lympho-reticuloendothelial system. To gain a better understanding of the physiological and biochemical nature of this enhancement, the metabolism of prostaglandin endoperoxide PGH2 was followed in mouse peritoneal cells (PCs). Homogenates of PCs from normal, unstimulated mice yielded primarily prostacyclin (PGI2) when incubated with PGH2. Homogenates of PCs from mice injected with the immunomodulators C. parvum, levamisole HCl, pyran copolymer, or thioglycollate yielded less PGI2. Reductions ranged from 73% for C. parvum to 32% for levamisole. A statistically significant inverse correlation existed between the level of macrophage "activation" and ability of cellular homogenates to produce prostacyclin. The results suggest that prostacyclin may be involved in modulation of nonspecific resistance.

Animals↗
PubMed1978

Hapten mimic elicits antibodies recognizing prostaglandin E2.

Antibodies that recognized the prostaglandin (PG) E structure were elicited from rabbits. 9-Deoxy-9-methylene-PGF2alpha, a stable isosteric mimic of PGE2, was conjugated to two different protein immunogens and the immune response system was duped into producing antibodies with poor recognition for prostaglandins other than the hapten mimic (9-deoxy-9-methylene-PGF2alpha) and its isosteric counterparts (PGE1 and PGE2). With this procedure, crossreaction that would ordinarily arise from the chemical or metabolic instability of an authentic PGE2 immunogen was avoided. Antibodies raised against a keyhole limpet hemocyanin conjugate of 9-deoxy-9-methylene-PGF2alpha had an average intrinsic association constant, Ko = 2.6 X 10(9) liters.mole-1, for PGE2. Crossreaction was low for a number of related prostaglandins, and a sensitive radioimmunoassay procedure with a detection limit of 6 pg was developed.

Animals↗
PubMed1978

Gas chromatography of the prostaglandins.

Gas chromatography is the most widely used chromatographic technique. Its strength lies in the fact that three distinct operations--separation, detection, and quantitation--can be performed on all the components of mixtures within a reasonable time, and that qualitative information about the compound identity is associated with its retention time. Despite a prominent position in other areas of biochemistry, its success in the prostaglandin field has been rather limited. The technique itself is not at fault since samples with reasonable levels of prostaglandins have been analyzed without overwhelming difficulty. However, many samples demand a sensitivity exceeding the limits of either electron capture or flame ionization detectors. Shifts in research problems have contributed to its decline, but it is fair to add that these shifts were associated with the appearance of more sensitive and accurate analytical methods. Let us not despair for gas chromatography because its competitors, radioimmunoassay and gas chromatography-mass spectroscopy, also have deficiencies. In this chapter we have described several traditional gas chromatographic methods for prostaglandin analysis and outlined their strengths and weaknesses. Hopefully, this will prevent the misapplication of a useful analytical tool and also serve as an incentive to provoke contributions to this somewhat neglected technology. In conclusion, it cannot be stressed enough that all instrumental methods are at the mercy of chemistry. Chemistry can be exploited to enhance the value of a technique, or it can be disregarded to discredit the technique. The rise of sophisticated instruments has falsely diminished the value of chemistry in analytical methods development. It is imperative that we remind ourselves of its place and use it properly.

Animals↗